文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫功能低下急性低氧性呼吸衰竭患者接受高流量鼻导管氧疗的结局

Outcomes in immunocompromised patients with acute hypoxemic respiratory failure treated by high-flow nasal oxygen.
PubMed 文献 · Intensive Care Med · 2025-04-22
一句话结论免疫功能低下合并急性低氧性呼吸衰竭患者接受高流量鼻导管氧疗,需插管机械通气者占46%,28天死亡率为33%,实体器官移植受者结局优于血液系统恶性肿瘤或实体瘤患者。

该多中心队列纳入986例接受高流量鼻导管氧疗的免疫功能低下急性低氧性呼吸衰竭患者,中位年龄63岁,66%为男性;免疫抑制原因以血液系统恶性肿瘤(55%)、实体瘤(30%)和实体器官移植(10%)为主,急性低氧性呼吸衰竭病因以细菌性肺炎(40%)和机会性感染(15%)最常见。46%的患者需有创机械通气,28天死亡率为33%;实体器官移植受者死亡率70%,血液系统恶性肿瘤患者48%,实体瘤患者51%。需有创机械通气者死亡率最高,尤其是髓系恶性肿瘤或病毒性肺炎患者;较低的ROX指数、较高的呼吸频率和较低的PaO2/FiO2比值是有创机械通气的预测因素。作者认为,优化治疗并识别高危患者可能改善结局,需前瞻性研究改进高流量鼻导管氧疗策略。

要点

  • 免疫功能低下急性低氧性呼吸衰竭患者接受高流量鼻导管氧疗,46%需有创机械通气,28天死亡率为33%。
  • 实体器官移植受者28天死亡率70%,血液系统恶性肿瘤患者48%,实体瘤患者51%。
  • 需有创机械通气者死亡率最高,尤其是髓系恶性肿瘤或病毒性肺炎患者。
  • 有创机械通气的预测因素包括较低的ROX指数、较高的呼吸频率和较低的PaO2/FiO2比值。
  • 急性低氧性呼吸衰竭病因以细菌性肺炎(40%)和机会性感染(15%)最常见。

适用人群与场景

  • 多中心队列纳入986例免疫功能低下的急性低氧性呼吸衰竭患者,均接受高流量鼻导管氧疗。
  • 免疫抑制原因包括血液系统恶性肿瘤(55%)、实体瘤(30%)和实体器官移植(10%)。
  • 急性低氧性呼吸衰竭病因包括细菌性肺炎(40%)和机会性感染(15%)。

研究设计与关键结果

  • 多中心队列研究,纳入986例接受高流量鼻导管氧疗的免疫功能低下急性低氧性呼吸衰竭患者,中位年龄63岁(IQR 54-70),66%为男性。
  • 46%的患者需有创机械通气,28天死亡率为33%。
  • 实体器官移植受者28天死亡率70%,血液系统恶性肿瘤患者48%,实体瘤患者51%。
  • 有创机械通气的预测因素包括较低的ROX指数、较高的呼吸频率和较低的PaO2/FiO2比值。
  • 需有创机械通气者死亡率最高,尤其是髓系恶性肿瘤或病毒性肺炎患者。

证据类型、等级与局限

  • 证据类型:多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,优化治疗并识别高危患者可能改善结局,需前瞻性研究改进高流量鼻导管氧疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Acute hypoxemic respiratory failure (ARF) is a major challenge in immunocompromised patients, often complicated by severe respiratory distress and organ dysfunction. High-flow nasal oxygen (HFNO) therapy is the standard of care, but data on its effectiveness and outcomes are limited. This study evaluated the outcomes of HFNO in this population, predictors of invasive mechanical ventilation (IMV), and factors associated with 28-day mortality.

METHODS: We analyzed data from a multicenter cohort of 986 immunocompromised patients with ARF treated with HFNO. Predictive factors for IMV and mortality were assessed using multivariable survival models, and the predictive value of the respiratory rate‑oxygenation (ROX) index for IMV was evaluated.

RESULTS: Patients had a median age of 63 years [IQR 54-70], and 66% were male. Primary causes of immunosuppression included hematologic malignancies (55%), solid tumors (30%), and solid-organ transplantation (10%). Bacterial pneumonia (40%) and opportunistic infections (15%) were the most common ARF etiologies. IMV was required in 46% of patients. Day 28 mortality was 33%, with better outcomes for solid-organ transplant recipients compared to hematologic malignancy or solid tumor (70% vs. 48% vs. 51% mortality, respectively). Predictors of IMV included a lower ROX index, higher respiratory rates, and lower PaO2/FiO2 ratios. Mortality was highest among patients requiring IMV, particularly those with myeloid malignancies or viral pneumonia.

CONCLUSIONS: HFNO outcomes in immunocompromised patients with ARF vary widely, influenced by immunosuppression type, ARF etiology, and clinical factors. Optimizing treatment and identifying high-risk patients could improve outcomes. Prospective studies are needed to enhance HFNO strategies.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Azoulay E, Métais M, Lemiale V, et al. Outcomes in immunocompromised patients with acute hypoxemic respiratory failure treated by high-flow nasal oxygen. Intensive Care Med. 2025. PMID: 40261380. doi:10.1007/s00134-025-07890-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。